Introduction
============

The importance of the renin-angiotensin-system (RAS) in the development of hypertension and cardiovascular disease is well established ([@b114]). Chronic RAS activation has been identified as a major factor contributing to progressive dysfunction of end organs including blood vessels, the kidneys and the heart ([@b114]). This prompted the development of agents, capable of blocking the RAS and reversing the associated pathologies.

The first group of drugs targeting the RAS which became available in the late 1970-ies were ACE-inhibitors (ACE-I) ([@b15]). Captopril was the first ACE-I which was and still is clinically used for the treatment of hypertension. The first--although peptide -- AT~1~-receptor-blocker (ARB) saralasin was identified in 1971 ([@b82]) and the antihypertensive effect demonstrated in patients in 1979 ([@b21]). Due to the lack of oral bioavailability this agent did not achieve wider clinical use. More than ten years elapsed before the first selective synthetic AT~1~-receptor antagonist (Losartan) became available for the treatment of hypertension ([@b66]). It soon became clear that the reduction in cardiovascular events demonstrated in clinical trials with ACE-I ([@b120]) and ARBs ([@b87]) was not only related to their blood pressure lowering capacity ([@b16]; [@b53]; [@b28]) but to a more complex effect in which reversal of target organ damage might be explained by inhibition of synthesis or activity of angiotensin II (Ang II) or transformation to a metabolite with pleiotropic activity.

The understanding of the RAS has been extended in the last few years with respect to the recognition that angiotensin-(1--7) \[Ang-(1--7)\] -- a metabolite cleaved from Ang I and Ang II -- is a biologically active product of the renin-angiotensin cascade ([@b20]). This heptapeptide has been recognized to counterbalance the effects of Ang II by stimulating the activity of vasodilator autocoids and nitric oxide (NO) ([@b41]). The characterization of Ang-(1--7) ([@b101]; [@b17]; [@b40]) as an amino-terminal angiotensin peptide product generated from either angiotensin I (Ang I) or Ang II provided a foundation for the pursuit of a new concept regarding the regulation of cardiovascular function by the RAS. While prostacyclin, bradykinin and NO act as vasodilator hormones limiting the pressor and proliferative actions of Ang II, it had not been considered that products derived independently from either angiotensin I (Ang I) or Ang II could also function to counterbalance the actions of Ang II.

This review focuses on the currently available evidence for the contribution of the vasodilator peptide Ang-(1--7) to the beneficial effects of cardiovascular drugs blocking the RAS and discusses the different pharmacological actions of ACE-I and ARBs on the balance of different RAS-effectors and the potential of new concepts like vasopeptidase and renin inhibition.

Ang-(1--7)
==========

Ang-(1--7) as an antagonist of angiotensin II
---------------------------------------------

Eighteen years ago the presence of the heptapeptide Ang-(1--7) as a product of the metabolism of Ang I found in brain homogenates ([@b94]) led to the later demonstration of its action in counteracting the pressor and baroreflex effects of Ang II ([@b17]; [@b8]; [@b9]). The existence of biologically active fragments, other than Ang II, suggests a process of biotransformation involving a cascade of multiple upstream enzymes but also raises the problem that the organization of the physiological network determining the actions of Ang II needs revision to account for the actions of the additional peptides. [Figure 1](#fig1){ref-type="fig"} gives an overview about the pathways for the formation of biologically active angiotensin peptides. Two important and recently published findings provide strong evidence for an extended understanding of the RAS as a regulatory system which does not necessarily have to be pharmacologically inhibited in order to treat hypertension and RAS-mediated end-organ damage but which can be pharmacologically modified by amplifying pathways generating Ang-(1--7). This has the potential to counterbalance the detrimental effects of Ang II: First, identification of the ACE-homologue ACE2 which forms Ang-(1--7) from Ang II ([@b36]; [@b109]; [@b29]) and second the identification of the *mas*-receptor ([@b99]) as molecular target structure for the Ang-(1--7)-molecule mediating its beneficial effects.

![Pathways for the formation of biologically active angiotensin peptides.\
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![Systematic overview of angiotensinogen (its crucial n-terminal part), angiotensin I, angiotensin II, and angiotensin-(1-7) with sites of enzymatic cleavage.](vhrm0301-125-02){#fig2}

Origin of Ang-(1--7)
--------------------

Ang-(1--7) is a fragment of Ang I which can be cleaved by endopeptidases through the removal of the last three amino acids of the Ang I precursor molecule. The relative importance of the endopeptidases, prolyl endopeptidase 24.26 (PEP), neutral endopeptidases (NEP) 24.11 (neprilysin), and thimet oligopeptidase 24.15 in the conversion of Ang I into Ang-(1--7) appears to depend on both tissue enzyme distribution and substrate availability since neprilysin is highly active in the circulation and vascular endothelium whereas in vascular smooth muscle Ang-(1--7) formation is dependent on the hydrolytic activity of thimet oligopeptidase 24.15 ([@b116]; [@b25]).

More recently, however, a pathway for Ang-(1--7) production has been demonstrated through the cloning and characterization of an ACE homologue--termed ACE2. This enzyme, shown to convert Ang II into Ang-(1--7) established a new pathway by which the trophic, vasoconstrictor, and pro-fibrotic effects of Ang II would be mitigated by this alternate processing pathway (see [Figure 1](#fig1){ref-type="fig"}).

ACE2 was identified as a new homologue of ACE ([@b36]; [@b109]; [@b29]) which -- in contrast to ACE -- is not inhibited by ACE-I nor does it share the same catalytic properties. The catalytic activity of ACE2 on Ang II as a substrate is much higher than its ability to cleave Ang-(1--9) from Ang I. ACE2 exhibits the highest efficacy (kcat/km) among Ang-(1--7)-forming enzymes and a 500-fold greater kcat/Km for Ang II compared with Ang I. Determination of the *kcat/Km* ratio gives a measurement of the substrate specificity. Thus, ACE2 appears to function to decrease Ang II concentration. ACE2 exists in both soluble and membrane-bound forms with high expression in the kidney, heart, cardiovascular tissues, brain and testes ([@b52]). Animal studies in the ACE2 knockout model demonstrated higher circulating and tissue levels of Ang II suggesting that reductions in ACE2 expression may lead to higher endogenous levels of Ang II and contribute to cardiac and renal pathologies associated with this model ([@b29]). Therefore, ACE2 might have an important function as a counter-regulatory enzyme to decrease local cardiac Ang II concentrations.

A way to degrade Ang-(1--7) is ACE which hydrolyses Ang-(1--7) to Ang-(1--5), thus regulating/limiting the physiological effects of Ang-(1--7) ([@b26]; [@b32]).

Ang-(1--7) receptor
===================

Several studies gave evidence for the existence of a non-AT~1~/AT~2~-receptor that mediates the effects of Ang-(1--7) ([@b108]; [@b18]; [@b35]; [@b62]). This was obtained using the selective Ang-(1--7)-antagonist A-779 ([@b4]; [@b97]). In addition, studies in *mas-*recep-tor transfected cells using Ang-(1--7) or the non-peptide Ang-(1--7)-agonist AVE-0991 showed that the *mas*-receptor mediates the effect of Ang-(1--7) on prostaglandins and NO release ([@b99]; [@b86]). Recent studies using antisense probes directed to the cardiac *mas* receptor further showed abolition of the anti-hypertrophic effects of Ang-(1--7) on cardiac myocytes ([@b107]). These effects were not blocked by specific AT~1~--or AT~2~-receptor-blockers. The *mas* proto-oncogene encodes a seven-transmembrane -- domain G-protein-coupled orphan receptor that was erroneously identified as an Ang II receptor in the late 1980ies. *mas* mRNA has been detected in the heart, testes, kidney, and the brain ([@b76]). Isolated hearts of *mas*-deficient mice (see ([@b115]) for details about the phenotype of *mas*-deficient mice) showed marked changes in cardiac function. The interaction of Ang-(1--7) with its *mas*-receptor may have an important role in the regulation of cardiac function ([@b23]). Today it is known that the *mas*-receptor mediates antiproliferative and antiarrhythmic effects, leads to vasodilation via bradykinin (BK) and NO-release, and stimulates renal sodium excretion and the sympathetic nervous system function.

Ang-(1--7) actions in preclinical studies
=========================================

Renal actions of Ang-(1--7)
---------------------------

The RAS is a key regulator of kidney function, playing an essential role in the homeostasis of blood volume and hydro-electrolyte balance ([@b49]). Evidence suggests that not only Ang II but also Ang-(1--7) plays a significant role in renal function. Ang-(1--7) has been described as a potent diuretic and natriuretic agent ([@b5]; [@b33]; [@b51]). It increases the renal blood flow in anesthetized rats ([@b93]) and produces afferent arteriolar relaxation through specific receptor-mediated NO-release in isolated kidneys of rabbits ([@b89]). In humans, the concentration of Ang-(1--7) in renal veins is several times higher than in the systemic circulation ([@b2]). In addition, Ang-(1--7) is excreted into the urine of normal healthy volunteers in amounts 2.5 fold higher than measured in the plasma ([@b44]). Control studies in untreated hypertensive patients showed a significantly reduced excretion of Ang-(1--7). Importantly, urinary concentrations of Ang-(1--7) showed an inverse correlation with blood pressure and were suggestive for the association with hypertension. The relatively higher concentrations of Ang-(1--7) in urine compared with plasma provide evidence that locally produced Ang-(1--7) may contribute to the regulation of renal function.

Cardiovascular actions of Ang-(1--7)
------------------------------------

Ang-(1--7) is formed ([@b95]) and metabolized ([@b26]) in endothelial cells. Vasorelaxant effects of the peptide have been demonstrated in animals in several vascular beds (see [Table 1](#tbl1){ref-type="table"}). Ang-(1--7)-induced vasorelaxation mainly results from amplification of bradykinin-induced dilation, by stimulation of vasodilator prostaglandins and by mediation of NO-release. In some vascular beds data suggest a role for Ang-(1--7) in mediating EDRF -- vasodilation. The biological actions of Ang-(1--7) are both activation of peripheral vasodilatory mechanisms and antitrophic effects mediated by the inhibition of protein synthesis (see [Table 2](#tbl2){ref-type="table"}). Ang-(1--7) exerts biological effects on three critical organ systems regulating blood pressure (brain, blood vessels, and kidney). The most important studies providing evidence for active vascular effects of Ang-(1--7) are summarized in [Table 3](#tbl3){ref-type="table"}. Preclinical studies demonstrate an important action of Ang-(1--7) in potentiation of the vasodilator actions of bradykinin. [@b92]) showed in human internal mammary arteries that contractions induced by Ang I and Ang II were antagonized by Ang-(1--7) in a non-competitive way, with a 60% inhibition of the maximal response to Ang II. The data further revealed an ACE-inhibiting effect by Ang-(1--7) in plasma and atrial tissue up to 100%. At supraphysiologic concentrations a vasoconstrictive effect of Ang-(1--7) has also been postulated -- most likely through a weak AT~1~-receptor agonist action ([@b96]). The observation that Ang-(1--7) increases following long-term-administration of ACE-I and ARBs ([@b96]) raises the possibility that Ang-(1--7) might contribute to the pharmacological effects of both ACE-I and ARBs.

###### 

Cardiovascular actions of Ang-(1--7)

  Ang-(1--7) --- effect                                                                              Model                                         Study
  -------------------------------------------------------------------------------------------------- --------------------------------------------- ----------
  Amplification of vasodilation mediated by bradykinin                                               Conscious rats                                ([@b83])
  Reduction of NE-release acting through a BK/NO-mediated mechanism stimulating cGMP/PKG-signaling   Hypertensive rat                              ([@b48])
  Coronary vasodilation mediated by NO                                                               Canine coronary arteries in vitro             ([@b14])
  Release of vasodilator prostaglandins                                                              Sprague-Dawley rats                           ([@b8])
  Reduction in plasma vasopressin concentration, blood pressure reduction                            Hypertensive rats                             ([@b10])
  Active vasodilation                                                                                Isolated rabbit afferent arterioles           ([@b89])
  Bradykinin potentiation                                                                            Arterioles hypertensive rats in vivo          ([@b38])
  Release of NO by Ang-(1--7)                                                                        Porcine coronary endothelium                  ([@b88])
  Stimulation and release of vasodilator prostaglandins                                              Porcine aortic endothelial cells              ([@b62])
  Induction of bradykinin-mediated hypotensive responses                                             Anesthetized rat                              ([@b1])
  Augmentation of bradykinin-induced vasodilation                                                    Canine coronary artery rings                  ([@b69])
  Endothelium-dependent relaxation                                                                   Canine middle cerebral artery                 ([@b46])
  Cerebral vasodilation mediated by prostaglandins                                                   Piglet pial arterioles                        ([@b75])
  Vasodilation mediated by EDRF                                                                      Feline mesenteric vascular bed                ([@b81])
  Relaxation potentiated by losartan                                                                 Rat aorta                                     ([@b68])
  Vasodilation in the cutaneous and implant vasculature                                              Newly formed vasculatures (sponge implants)   ([@b71])
  Bradykinin-induced vasodilation by Ang-(1--7)                                                      Anestethized Wistar Rats                      ([@b80])
  Unmasking of a bradykinin mediated potentiation of ACE-inhibitors                                  Spontaneously hypertensive rats               ([@b38])

**Abbreviations**: See Figure 1.

###### 

Biological actions of Ang-(1--7)

  Organ or system    Biological action                                          Reference
  ------------------ ---------------------------------------------------------- -------------------------------------------------
  Cellular actions   • Stimulation of release of PGE2 and 6-keto-PGF1~α~        ([@b111]; [@b62], [@b63], [@b64]; [@b10])
                     • Augmentation of the vasodilator action of bradykinin     ([@b88]; [@b97]; [@b83]; [@b1]; [@b69]; [@b70])
                     • Increased release of NO                                  ([@b81]; [@b14]; [@b1]; [@b69])
                     • Antiproliferative actions in vascular smooth muscle      ([@b47])
  Brain              • Stimulation of vasopressin release                       ([@b101]; [@b7]; [@b98])
                     • Facilitation of baroreflexes                             ([@b17]; [@b18]; [@b104])
  Blood vessels      • Vasodilation and antihypertensive actions                ([@b8], [@b9], [@b10])
  Kidney             • Diuresis and natriuresis                                 ([@b33]; [@b51]; [@b5]; [@b56])
                     • Inhibition of tubular sodium and bicarbonate transport   ([@b50], [@b51])

**Abbreviations**: See Figure 1.

###### 

Interactions between Ang-(1--7), kinins, and Ang II in kidney and blood vessels

  Action                                               Model                                                                                  Reference
  ---------------------------------------------------- -------------------------------------------------------------------------------------- --------------------
  Potentiation of bradykinin by Ang-(1--7) by kinins   • Normo- and hypertensive rats                                                         • ([@b96])
                                                                                                                                              • ([@b83])
                                                                                                                                              • ([@b38])
                                                       • Canine coronary arteries                                                             • ([@b14]; [@b69])
                                                       • Isolated rat hearts                                                                  • ([@b3])
                                                       • Conscious male Wistar rats                                                           • ([@b11])
                                                       • Chinese hamster ovary cells transfected with human cDNA for BK-B2receptors and ACE   • ([@b32])
  Mediation of Ang-(1--7) actions by kinins            • Canine coronary arteries                                                             • ([@b14]; [@b69])
                                                       • Conscious male Wistar rats                                                           • ([@b11])
                                                       • Bovine aortic endothelial cells                                                      • ([@b55])
                                                       • Anesthetized rats                                                                    • ([@b1])

### Interaction with bradykinin

Most of the interactions between Ang-(1--7) and bradykinin (BK) have been reported to occur in blood vessels ([@b83]; [@b14]; [@b54]; [@b69]; [@b96]; [@b3]; [@b38]). Two major types of interactions are postulated: 1. potentiation of BK by Ang-(1--7) and 2. mediation of the vascular actions of Ang-(1--7) by kinins. An overview about the currently available study evidence demonstrating interactions between bradykinin and Ang-(1--7) is summarized in [Table 3](#tbl3){ref-type="table"}. The mechanism underlying the BK potentiating activity of Ang-(1--7) is complex: There is considerable evidence for *mas*-receptor-mediated facilitation of NO release ([@b69]; [@b3]; [@b55]) and/or prostaglandins ([@b83]; [@b3]; [@b38]), endothelium-derived hyperpolarizing factor ([@b38]), binding to ACE and because of that facilitation of the crosstalk between ACE and BK-B~2~ receptors ([@b32]) and ACE-inhibition ([@b69]; [@b26]). It is assumed that the relative contribution of each of these mechanisms changes from vascular bed to vascular bed, with species and probably with vessel diameter ([@b96]).

Role of Ang-(1--7) as physiologic antagonist of angiotensin II
--------------------------------------------------------------

The first study describing an interaction between Ang-(1--7) and Ang II was published by [@b13]) who described inhibition of the contractile effect of Ang II in the rabbit aorta by the Ang-(1--7) analogue Sar^1^-Ang-(1--7). Several studies confirmed the ability of Ang-(1--7) to antagonize the vascular effects of Ang II ([@b73]; [@b92]; [@b112]). Most evidence about the physiological actions of Ang-(1--7) has been demonstrated in animal models. However, there is also evidence from human studies: In a study performed in the arterial vascular bed of healthy young men, Ang-(1--7) was able to antagonize Ang II-induced vasoconstriction ([@b112]) by shifting the dose-response-curve of Ang II to the right. Several mechanisms have been suggested for this interaction of Ang-(1--7) and Ang II in blood vessels: The weak constrictive effect described in the study by [@b112]) (humans) and in the studies of [@b1]) and [@b10]) (animals) is mediated by low binding of Ang-(1--7) to the AT~1~-receptor causing an agonistic effect.Interaction of Ang-(1--7) with extracellular Ca^2+^ influx into smooth muscle cells might also contribute to this weak constrictive effect ([@b24]).Because Ang-(1--7) does not antagonize the vasoconstrictor action of α-adrenergic drugs in vitro ([@b73]) or in human forearm ([@b112]) it seems unlikely that these effects contribute to its antagonistic effects of Ang II-actions.An influence of Ang-(1--7) on the synthesis of Ang II at the mRNA-level has been described ([@b78]).ACE-inhibiting properties of Ang-(1--7) have been described ([@b69], [@b110]) based on a crosstalk between ACE and the BK-B~2~ receptor and *mas*-receptor-mediated changes in the coupling and/or signalling of bradykinin.A crosstalk between the *mas*-receptor and other receptors such as AT~1~-and AT~2~-receptors may counterbalance constrictive pathways towards pathways resulting in vasodilation.Ang-(1--7) potentiates the vasodilatory and hypotensive effects of bradykinin ([@b83]; [@b80]; [@b3]; [@b110]).

Interpretation of currently available study evidence with Ang-(1--7) in humans
------------------------------------------------------------------------------

All human trials investigating the cardiovascular effects of Ang-(1--7) are summarized in [Table 4](#tbl4){ref-type="table"}. Sasaki and co-workers ([@b100]) reported vasodilation in the human forearm whereas Davie and McMurray ([@b31]) did not observe an acute hemodynamic short-term effect of Ang-(1--7) in ACE-I treated patients. Failure to obtain a vasodilator response in patients given an ACE-I is not surprising as this treatment is associated with increased Ang-(1--7) levels due to both prevention of peptide metabolism by ACE and increased production from elevated levels of Ang I. In keeping with this interpretation, increased circulating Ang-(1--7)-levels have been clearly demonstrated in humans after therapy with RAS-inhibitors ([@b26]; [@b61]; [@b31]). Even if we assume that there is only a weak or even no agonistic short-term effect of Ang-(1--7) -- infusion favoring vasodilation in the human forearm vascular bed, this does not exclude hemodynamic effects in other vascular beds (eg, veins) or beneficial long-term-effects after drug therapy with ACE-I or ARBs mediated by increases in Ang-(1-7)-peptide levels. It has to be noted that the long-term effects of ACE-I and ARBs on Ang-(1--7)-metabolism have not been investigated in humans so far.

###### 

Studies investigating the effects of Ang-(1--7) in humans

  Author      Subjects                                                                  Methods                                                                                                                          Results                                                                                                                Interpretation
  ----------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ([@b92])    Human arteries in vivo                                                    Internal mammary arteries; Incubation with Ang-(1--7) IC 50: 3 and 4 mmol/L                                                      • ACE activity in plasma and atrial tissue was inhibited by Ang-(1--7) up to 100%                                      • Ang-(1--7) blocks Ang II induced vasoconstriction and inhibits ACE in human cardiovascular tissues
                                                                                                                                                                                                                                                                                                                                                • Ang-(1--7) may be an important modulator of the human RAS.
  ([@b31])    Patients with heart failure on treatment with an ACE-inhibitor            Brachial artery infusions of Ang-(1--7), venous occlusion plethys-mography; 5--50.000 pmol/min.                                  • No effect of Ang-(1--7) on its own or any effect of Ang-(1--7) on the response to bradykinin                         • Ang-(1--7) is biologically inactive in the forearm circulation of patients with heart failure treated with an ACE-inhibitor
  ([@b112])   Healthy normotensive men, forearm arteries                                Brachial artery infusions of Ang-(1--7) 0.1--2000 pmol/min.                                                                      • Ang-(1--7) at 0.5--40 nmol/min caused weak but significant vasoconstriction                                          • Ang-(1--7) antagonizes vasoconstriction by Ang II in human resistant vessels and might act as an endogenous Ang II antagonist
                                                                                                                                                                                                                         • Ang-(1--7) at 100 pmol/min, but not at 10 pmol/min, significantly shifted the Ang II DRC towards the right           
                                                                                                                                                                                                                         • Ang-(1--7) did not affect the DRC of NA                                                                              
  ([@b113])   Normotensive healthy men, forearm arteries                                Coinfusion of bradykinin with placebo, Ang-(1--7) 1000 pmol/min, Angiotensin II and L-NMMA                                       • Ang-(1--7) potentiated bradykinine-induced vasodilation                                                              • Ang-(1--7) potentiates the vasodilating effect of bradykinin through mechanisms involving nitric oxide release in human forearm resistance vessels.
                                                                                                                                                                                                                         • Dilation was completely abolished by L-NMMA                                                                          
                                                                                                                                                                                                                         • Ang-(1--7) did not affect the vasodilating effects of Acetylcholine or nitro-prusside                                
  ([@b118])   Normotensive healthy men Human forearm resistant vessels                  Intraarterial infusion of Ang-(1--7) (10, 100, 300 pmol/min), bradykinin (47, 94, 189 pmol/min and Ang I (1, 10, 30 pmol/min.)   • No effect of Ang-(1--7) on forearm blood flow                                                                        • Does not support a role of Ang-(1--7) given at supraphysiological doses in the regulation of human peripheral vascular resistance
  ([@b100])   Patients with essential hypertension and normo-tensive control subjects   Intraarterial infusion of Ang-(1--7) 10^−10^, 10^−9^, 10^−8^ mol/min                                                             • Ang-(1--7) infusion significantly increased forearm bloodflow dose-dependently in normo- and hypertensive patients   • Ang-(1--7) causes vasodilation in forearm circulation of normotensive subjects and patients with essential hypertension through a pathway independent of NO-synthesis
                                                                                                                                                                                                                         • Ang-(1--7)-induced dilation was similar in both groups                                                               
                                                                                                                                                                                                                         • L-NMMA coinfusion did not alter the forearm blood flow response to Ang-(1--7)                                        

**Abbreviations**: NA, noradrenaline.

Although it is not completely clear from human studies if exogenously infused Ang-(1--7) acts as a vasodilator ([@b118]), the available experimental evidence suggests that Ang-(1--7) contributes to the cardiovascular effects of ACE-I and ARBs by directly acting as an ACE-I or by an interaction with ACE favoring a crosstalk between the ACE-, the BK-B~2~- and the *mas*-receptor by mediating changes in coupling and signalling of bradykinin. However, randomized controlled studies systematically investigating the effects of RAS-blockade with ACE-I and ARBs on Ang-(1--7)-biology and catabolism have not been conducted. The main problem with the results obtained in human studies might be related to the extremely low case numbers included in clinical studies (usually n = 8) and to methodological differences in the study protocols. Therefore, the initiation of large randomized controlled clinical studies systematically investigating long-term-effects of pharmacological RAS-blockade on Ang-(1--7)-metabolism seems to be highly desirable.

We have recently demonstrated in healthy male subjects that a 4 week treatment period with 150 mg of the AT~1~-receptor-antagonist irbesartan results in significant increases of Ang-(1--7) peptide levels which points towards a contribution of Ang-(1--7) to the antihypertensive and beneficial vascular effects of AT~1~-receptor blockade ([@b102]). This study provides evidence that Ang-(1--7)-biol-ogy might also be involved in humans when inhibitors of the RAS are being used.

In addition it has to be noted that the majority of published human studies points towards a RAS-modulatory role of Ang-(1--7) in humans ([@b92]; [@b112]; [@b100]; [@b113]) supporting vasodilation. Especially the recent data showing a role for ACE2 in cardiopulmonary pathophysiology ([@b90]) and clinical data from healthy human subjects ([@b102]) suggest that the effects of drug treatment with ACE-I and ARBs merit another look with regard to Ang-(1--7)-biology and its relevant signalling pathways.

Pharmacologic RAS inhibitors and Ang-(1--7)
===========================================

Different actions of ACE-I and ARBs on the RAS
----------------------------------------------

The general ability of ACE-I and of ARBs to attenuate virtually all of the cardiovascular actions of the RAS is commonly accepted (for review see ([@b34])). Although ACE-I and ARB block the same system, they have important mechanistic differences because they act on different sites of the RAS ([@b16]). The differences between the two drug classes have a differential impact on the affected angiotensin receptor subtypes, a different involvement of peptide hormones other than Ang II, and possible differences in the efficacy of RAS suppression. ACE-I reduce the stimulation of AT~1~ and AT~2~ receptors, but inhibition may be overcome by activation of renin, by induction of ACE, and by alternative Ang II forming enzymes such as chymase. Inhibition of ACE blocks the degradation of various peptides, especially the vasodilator bradykinin. ACE-I potentiate the effects of bradykinin by 3--50-fold ([@b12]). Bradykinin stimulates NO-release from endothelial cells via B~2~-receptors ([@b114]). These effects might contribute to the antihypertensive effects of ACE-I.

Effect of ACE-I and ARBs on Ang-(1--7) generation
-------------------------------------------------

Drug therapy with an ACE-I compared with ARB-therapy exerts different effects on the RAS-balance. Pharmacologically blocking ACE results in lower circulating Ang II peptide levels which means that less substrate is available for ACE2 and for Ang-(1--7)-generation. The catabolism of Ang-(1--7) and Ang II-levels is decreased by ACE-I-treatment, whereas the level of Ang I which is a substrate for Ang-(1--7)-forming enzymes to generate Ang-(1--7) is increased. Ang-(1--7) can then act via the *mas*-receptor (see also [Figure 1](#fig1){ref-type="fig"}). The observation that the Ang-(1--7) antagonist D-Ala7-Ang-(1--7) reverts the potentiation of bradykinin by enalapril or enalaprilat in mesenteric microvessels ([@b38]), or attenuates the potential hypotensive response to BK in captopril-treated rats ([@b74]) indicates that an Ang-(1--7)-related mechanism significantly contributes to the hypotensive and beneficial effects of ACE-I.

ARBs completely block all effects mediated via the AT~1~-receptor which results in increased Ang II levels. This increase in circulating Ang II levels causes a shunting of Ang II to the unopposed AT~2~-receptor. It has been demonstrated experimentally that AT~2~-receptor stimulation enhances bradykinin-generation, so that some vasodilator or diuretic actions of ARB may arise through this pathway ([@b19]). However, bradykinin potentiation by ARBs is less to that of ACE-I which might have impact on the therapeutically desired actions. On the other hand, AT~1~-receptor blockade prevents the AT~1~-mediated actions of Ang II and might hence be capable of potentiating its effects via AT~2~-receptors. However, work by Ferrario and colleagues found no evidence for a role of AT~2~-receptors in mediating the vasodilator response produce by long-term administration of lisinopril and losartan ([@b60], b, [@b59]). In addition, increased levels of both Ang I and Ang II change the metabolic cascade through ACE2 towards Ang-(1--7)-generation as recent work demonstrated that administration of either losartan or olmesartan upregulated cardiac and renal ACE2 mRNA ([@b58]; [@b42], b; [@b57]; [@b65]). ACE-I and ARBs have important similarities because they block the same system but they also have several differences in their mechanisms of action, eg, regarding their effects on kinins, Ang-(1--7) and the AT~2~-receptor. The clinical relevance of these different therapeutic principles of RAS-blockade requires further study. Although beyond the scope of the present article there is also increasing interest and evidence to support the combined use of ACE-I and ARB in various clinical settings such as heart failure ([@b16]). The Candesartan in Heart Failure Assessment of Reduction in Morbidity and mortality (CHARM) trial revealed that candesartan treatment significantly reduced cardiovascular deaths and hospital admissions for heart failure ([@b85]). In addition, the COOPERATE-trial highlighted that combination treatment of an ACE-I with an ARB safely retards progression of non-diabetic renal disease compared with monotherapy ([@b79]).

What this means in terms of the regulations and interplay of the components of the RAS is still widely unknown.

Is there scientific evidence for therapeutic superiority of either ARBs or ACE-I for any medical indication?

ACE-I and ARBs are successfully applied in the treatment of hypertension, heart failure, diabetes and coronary heart disease ([@b34]). Although ACE-I and ARBs block the same system, they may have important differences because they act on different sites of the RAS. However, therapeutic superiority of ARBs over ACE-I has never been proven. International treatment guidelines for hypertension ([@b27]) cite ACE-I and ARBs as equally effective in reducing blood pressure but explicitly recommend ARBs only in case of ACE-I induced cough ([@b106]). Although clinical trials with head to head comparison of ACE-I with ARBs are few, there is some evidence suggesting differences in their effect on insulin sensitivity ([@b77]) and pulse pressure ([@b105]). In addition, selective ARBs have consistently been shown to inhibit several physiologic mechanisms that are involved in the development of in-stent restenosis: neointimal formation, vascular smooth cell migration, oxidative stress, anti-inflammatory effects and suppression of smooth muscle cell differentiation. There is increasing evidence from clinical studies that ARBs reduce restenosis rates after coronary ([@b84]; [@b119]) or superficial femoral artery stenting ([@b103]) whereas ACE-I do not have these beneficial effects ([@b37]; [@b22]; [@b72]). Considering the pharmacological differences between ACE-I and ARBs it has to be pointed out that treatment with an ARB results in significantly increased Ang-(1--7)-peptide levels ([@b102]) whereas treatment with an ACE-I does not. Together with the experimental results of Langeveld ([@b67]) who described a significant reduction in neointimal thickness after Ang-(1--7) infusions in an experimental model after stent implantation one might speculate that increased Ang-(1--7)-levels might causally contribute to the improved outcomes documented with ARBs after vascular interventions whereas increased bradykinin-levels after treatment with an ACE-I do not seem to have beneficial vascular effects. This hypothesis should be confirmed in large, randomized controlled clinical studies.

However, the significance of most of the reported differences between the two drug classes remains largely unknown and in clinical practice the only clearly established advantage of ARBs over ACE-I is the absence of cough as a side effect.

Other cardiovascular drugs with therapeutic implications on the RAS
===================================================================

Renin-inhibitors
----------------

Experimental and clinical studies have indicated that blockade of the RAS is an important therapeutic strategy in reducing cardiovascular and renal disease. However, the therapeutic response achieved with currently available blockers of the RAS -- angiotensin-converting-enzyme-inhibitors and angiotensin receptor blockers -- although efficacious, is limited. This may be partly because of the reactive rise in renin induced by these agents with the resultant increase in angiotensin peptides. Therefore, other more effective strategies to block the RAS have been sought. Just recently a new renin inhibitor (aliskiren) was FDA-approved for the treatment of hypertension in April 2007 (for review see ([@b6])). Renin inhibitors prevent the formation of Ang I and Ang II and so may act differently from ARBs and ACE-I. Currently there is no published data from preclinical or clinical studies investigating the influence of pharmacological renin-inhibition on either urinary or serum peptide levels of Ang-(1--7).

Vasopeptidase-inhibitors
------------------------

Drugs that possess the ability to inhibit simultaneously ACE and the neutral endopeptidase 24.11 (NEP) represent another development of compounds affecting the RAS. These dual inhibitors, also named vasopeptidase inhibitors, decrease Ang II generation by inhibiting ACE activity, and reduce the metabolic degradation of natriuretic peptides by inhibiting NEP. Natriuretic peptides represent a family of peptides that include the atrial natriuretic peptide (ANP), the BNP, and the C-type natriuretic peptide (CNP). Bradykinin and substance P are two other peptides metabolized by ACE and NEP, the accumulation of which may contribute to the vasodilatory effects of dual inhibitors.

Ferrario et al ([@b39]) found a strong correlation between the antihypertensive response to omapatrilat and increases in urinary excretion rates of Ang I and Ang-(1--7) in spontaneously hypertensive rats and also in salt-sensitive hypertensive subjects ([@b45]) suggesting a contribution of Ang-(1--7) to the vasodilator response mediated by this agent. This important association between increases in both plasma and urinary Ang-(1--7) and the antihypertensive effect of omapatrilat suggests, even if it does not prove, that Ang-(1--7) as humoral regulator may play a contributing role in the mechanisms that account for the control of blood pressure.

However, omapatrilat as the prototype of drugs with this pharmacological principle of dual inhibition was clinically developed but never got final approval by the health authorities due to unforeseen side-effects.

Perspectives
============

Ang-(1--7) as potential cardiovascular drug target
--------------------------------------------------

Besides its direct vascular effects which are not completely clear in humans, Ang-(1--7) can act as an ACE-I and as an Ang II antagonist and facilitates the vascular and cardiac effects of bradykinin, making it an attractive target for the development of new cardiovascular drugs. The growing evidence that at least part of the beneficial effects of ACE-I and ARBs are mediated by Ang-(1--7) further strengthens this view. The recently described model compound AVE-0991 is the first available Ang-(1--7) receptor agonist. A recently published study ([@b117]) demonstrated that the new nonpeptide compound AVE 0991 is able to evoke effects on endothelial cells similar to that observed for heptapeptide Ang-(1--7). The amount of AVE 0991-stimulated NO production was about five times higher than that stimulated by Ang-(1--7) ([@b117]). In addition it was experimentally shown that AVE is an Ang-(1--7) receptor *mas*-receptor agonist ([@b86]). This promising drug characteristic makes the orally active Ang-(1--7)-agonist AVE-0991, as a potent mimic of the unique NO/O~2~-releasing profile of Ang-(1--7), an attractive target for further future development for patients, eg, for indications such as endothelial dysfunction and stable coronary heart disease. Besides their potential as vascular drugs Ang-(1--7) or other *mas*-receptor-agonists might also exert beneficial effects on structural organ disease such as myocardial fibrosis which is a key pathological process in left ventricular hypertrophy. The optimal treatment of hypertensive patients should target a parallel decrease in cardiac mass and fibrosis. Preliminary evidence suggests that not all antihypertensive agents affect fibrosis to the same extent. However, agents directly blocking the RAS such as ACE-I and ARBs appear particularly effective ([@b30]) which underlines that *mas*-receptor-agonists might have a therapeutic potential and should be systematically investigated for this indication.

In addition, the presence of polymorphisms in the Ang-(1--7) forming enzyme genes and ACE2 need further exploration as we showed that men with the T allele showed higher Ang-(1--7) levels compared with those with the MM genotype ([@b91]). Furthermore, additional studies should be directed to determine whether the efficacy of long-term effects of ACE-I or ARB on cardiac remodeling and preservation of renal function correlates with the effect of these drugs on plasma levels of Ang-(1--7).

Conclusion
==========

Ang-(1--7) as the most pleiotropic angiotensin peptide can act at several levels on the RAS, counterbalancing the detrimental vascular effects consequent to Ang I and Ang II formation and is therefore an attractive candidate as a therapeutic drug target. The majority of clinical studies investigating cardiovascular effects of Ang-(1--7) are in favor of beneficial RAS-modulating effects. Conflicting evidence about the RAS-modulating role of Ang-(1--7) reported from human studies might be related to extremely low case numbers investigated and due to different study protocols. The relevance of beneficial effects of Ang-(1--7) for patients on therapy with ACE-I or ARBs should therefore be systematically studied in randomized controlled trials in humans.
